Form 4: Telesis Bio Inc. President & CEO, Eric Eugene Esser, Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Eric Eugene Esser, President & CEO of Telesis Bio Inc., reports acquisition of stock options and restricted stock units.
Summary
- On April 17, 2024, Eric Eugene Esser, President & CEO of Telesis Bio Inc., was granted 100,000 restricted stock units (RSUs) and options to purchase 200,000 shares of common stock.
- The RSUs will vest in two equal installments on April 17, 2025, and April 17, 2026, contingent upon Esser's continued service.
- The stock options, with an exercise price of $0.38, will vest with 25% vesting on April 17, 2025, and the remaining 75% vesting monthly over the subsequent three years.
- Following these transactions, Esser directly owns 129,260 shares of Telesis Bio Inc. common stock and options to purchase 200,000 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of equity compensation is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no negative indicators in the filing.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CEO.
Industry Context
This type of equity compensation is common for CEOs in publicly traded companies, particularly in the biotech industry, to align their interests with shareholders and incentivize long-term growth.
Comparison to Industry Standards
- Equity compensation packages for CEOs in the biotech industry typically include a mix of stock options and restricted stock units.
- The vesting schedules are fairly standard, with vesting occurring over a period of several years to encourage long-term commitment.
- The specific amounts and terms of the grants would be benchmarked against peer companies of similar size and stage of development.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/17/2024 | Date of transaction: Grant of RSUs and stock options. |
| 04/17/2025 | First vesting date for 50% of RSUs and 25% of stock options. |
| 04/17/2026 | Second vesting date for remaining 50% of RSUs. |
| 04/17/2034 | Expiration date of stock options. |
Keywords
Telesis Bio Inc., Eric Eugene Esser, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, TBIO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.